NMD Pharma

NMD Pharma will be at the upcoming Synapse DK - Life Science Connect Career Fair in Aarhus on October 29, 2024. As a leading biotech company, we're always on the lookout for talented individuals to join our growing team as our lead program, NMD670, progresses through multiple clinical trials. If you’ve ever wondered what it’s like working for a #biotech company, Martin Brandhøj Skov, Innovation Manager, and Jesper Emil Jakobsgaard, Research Scientist, will be there to answer your questions and share insights into the dynamic world of #research in neuromuscular diseases. Martin will be giving a talk about NMD Pharma from 16:30-17:00. Sign up for the career fair here: https://lnkd.in/dW9NhUTB Check out what a day in the life of a research scientist at NMD Pharma looks like here: https://lnkd.in/d9AkuPQA #LifeScienceCareerFair #Innovation #ClinicalResearch #NeuromuscularDisease

Our CEO, Thomas Holm Pedersen and COO, Thomas Kongstad Petersen will be at the #BIOEurope conference in Stockholm, Sweden from 4-6 November. We look forward to connecting with other #biotech leaders and #investors and sharing the latest updates on NMD670, our novel chloride 1 ion channel (ClC-1) modulator skeletal muscle-targeted therapy with the potential to improve muscle power and endurance in patients living with severe neuromuscular diseases. If you are interested in learning more, please contact us by email contact@nmdpharma.com.   #InvestorConference #NMDPharma #Innovation #NeuromuscularDisease #Collaborations

Please join us in welcoming Trine Schütt to the NMD Pharma team as Senior #Toxicologist and Animal Welfare Officer. Trine is a veterinarian by training with a PhD in veterinary neurology. She comes with extensive experience within drug development from LEO Pharma where she was the Principal Professional/Developmental Toxicologist and Animal Welfare Officer.  In her new role at NMD Pharma she will work closely with the non-clinical development team to advance our pipeline molecules and furthermore ensure that all our operations and external collaboration partners are compliant with respect to high standards of animal welfare. Welcome Trine! #NewHire #WelcomeToTheTeam #NMDPharma #Biotech #Innovation

We’re pleased to announce that Alok Singh joined us last month as a Senior Data Manager at our office in Copenhagen. Alok has many years of experience in data management EDC set-up, conduct, and closeout, including at Ascendis Pharma, LEO Pharma and Novo Nordisk. With two Phase 2 trials of our lead development program, NMD670, already underway in spinal muscular atrophy (#SMA) and generalized myasthenia gravis (#MG), and a third in Charcot-Marie-Tooth disease anticipated to start shortly, Alok’s expertise will be invaluable as we continue to progress into a Phase 3-ready organization. Welcome to the team, Alok! #NMDPharma #Innovation #Research #NeuromuscularDisease

Next week, Vera K., Director of Clinical Development and Martin Brandhøj Skov, Innovation Manager at NMD Pharma will be giving three oral presentations and Dan Brennan, SVP Corporate and Commercial Strategy will be presenting a poster at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. Taking place from 15-18 October, this year’s programme offers a diverse selection of valuable in-person sessions with the world’s foremost academic and scientific experts in the field of #NeuromuscularDisease, alongside the latest cutting-edge #research. NMD Pharma’s oral and poster presentations will take place during the Myasthenia Gravis Foundation of America, Inc. (MGFA) Scientific Session, showcasing our preclinical and clinical work establishing the novel therapeutic potential of ClC-1 ion channel inhibition for several neuromuscular diseases, including myasthenia gravis (#MG). By inhibiting the CIC-1 channels, NMD670 amplifies muscle responsiveness, enabling consistent contractions even when the signal transmitted to the muscle is weak due to disease processes. The session will be held on Tuesday, 15 October from 8:00-12:00ET in Chatham Ballroom A – please stop by to learn more about our novel approach, or reach out to Dan to set up a meeting. For more information, read the full press release: https://lnkd.in/gd7CfQSR #Biotech #AANEMAnnualMeeting #AANEMinSavannah #NMDPharma #Innovation #MyastheniaGravis #MGFA #RareDisease

We are looking for a Senior Drug Substance Specialist! As NMD Pharma continues its growth trajectory following its successful recent fundraising, we are seeking a motivated and highly skilled late-stage drug substance specialist to contribute towards our mission of bringing life-changing therapies to patients living with neuromuscular diseases. Find out more here: https://lnkd.in/gPVcrJ9A

Looking for a new challenge as our next Team Leader, Administration? We seek a dynamic team member to help shape and optimize our administrative processes. Know someone who’s the perfect fit? Share this opportunity with them! Find out more and apply here: https://lnkd.in/gs5Z_3a5 We can’t wait to read your application!

Recently, NMD Pharma’s Jorge A. Quiroz and Martin Brandhøj Skov had the pleasure of attending the #GlobalCMTResearchConvention in Cambridge, MA, where they both presented how our work could potentially improve muscle function and endurance in patients living with neuromuscular diseases like #CMT to help them live better, more independent lives. The Convention offered the unique opportunity to engage with the CMT patient community, alongside other clinicians and researchers driving innovation in the space. It was great to see how many new therapies for this #RareDisease are being developed, many of which are driven research funded by CMT advocacy groups, and we are proud to be progressing our novel, skeletal muscle specific ClC-1 inhibitor approach through to clinical trials alongside them. Read more about neuromuscular diseases here: https://lnkd.in/dq_ZJtMs #NMDPharma #Biotech #NeuromuscularDisease #Innovation #ICYMI 

In case you missed it, our CEO and Founder, Thomas Holm Pedersen, was invited to participate in SMA Europe’s #WeAreOne campaign, speaking on behalf of all those researchers with a dream to make a tangible difference in spinal muscular atrophy (#SMA) communities around the world. This campaign, which was launched in August in honor of SMA awareness month, aims to unite the diverse experiences and needs of people living with this rare #NeuromuscularDisease under one shared dream: to create a better world for all those affected by SMA. Thomas began his #research career almost 30 years ago in the laboratories of Aarhus University and Cambridge University, where he developed his Passion for Movement and muscle physiology. It is this drive to make a difference that eventually led him to found NMD Pharma, a #biotech company focused on developing therapies for severe neuromuscular disorders, based on his learnings and ideas from over the years. We are proud to represent the companies and researchers in the space, and thank you to SMA Europe for recognising Thomas’s and NMD Pharma’s dedication to developing meaningful treatments with the potential to enable those living with SMA to live better, more independent lives. To watch the SMA Europe’s #WeAreOne documentary: https://lnkd.in/dyrhaHBM #ICYMI #SpinalMuscularAtrophy #SMAAwareness #Innovation #RareDisease #UniteForSMA #OneCommunitySharedDreams

Members of the NMD Pharma team will be on the ground in Prague, CZ for the 29th Annual Congress of the World Muscle Society, held from 8-12 October. As one of the largest meetings dedicated to the research and understanding of #NeuromuscularDisease and pathology, #WMS2024 is an important platform for the global community of scientists, healthcare professionals and other stakeholders to foster collaboration, share knowledge and discuss the latest cutting-edge #research. Teresa Gidaro, Director of Clinical Development, and Martin Broch-Lips, Director, Head of Biological Research, will present three abstracts, detailing our preclinical and clinical work investigating the therapeutic potential of CIC-1 ion channel inhibition to recover neuromuscular transmission and muscle function in myasthenia gravis (#MG) and Charcot-Marie-Tooth (#CMT) disease. If you are also attending, be sure to stop by the Forum Hall during Poster Sessions 1 and 4 for their presentations, or reach out to Teresa or Martin if you would like to learn more. For the event agenda, including full abstract names and presentation times: https://lnkd.in/dbyBmdSC #Conference #Biotech #Innovation